- Home
- CHRS vs ELA Comparison
CHRS vs ELA Comparison
Compare CHRS & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ELA
- Stock Information
- Founded
- CHRS 2010
- ELA 1965
- Country
- CHRS United States
- ELA United States
- Employees
- CHRS 235
- ELA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ELA Consumer Specialties
- Sector
- CHRS Health Care
- ELA Consumer Discretionary
- Exchange
- CHRS Nasdaq
- ELA Nasdaq
- Market Cap
- CHRS 134.4M
- ELA 173.1M
- IPO Year
- CHRS 2014
- ELA N/A
- Fundamental
- Price
- CHRS $1.22
- ELA $6.75
- Analyst Decision
- CHRS Strong Buy
- ELA Strong Buy
- Analyst Count
- CHRS 4
- ELA 1
- Target Price
- CHRS $5.38
- ELA $7.00
- AVG Volume (30 Days)
- CHRS 2.4M
- ELA 17.3K
- Earning Date
- CHRS 03-12-2025
- ELA 03-19-2025
- Dividend Yield
- CHRS N/A
- ELA N/A
- EPS Growth
- CHRS N/A
- ELA N/A
- EPS
- CHRS N/A
- ELA 0.25
- Revenue
- CHRS $304,340,000.00
- ELA $165,946,534.00
- Revenue This Year
- CHRS $2.47
- ELA $1.61
- Revenue Next Year
- CHRS N/A
- ELA $6.30
- P/E Ratio
- CHRS N/A
- ELA $27.13
- Revenue Growth
- CHRS 44.19
- ELA N/A
- 52 Week Low
- CHRS $0.66
- ELA $4.20
- 52 Week High
- CHRS $2.87
- ELA $7.88
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- ELA 42.74
- Support Level
- CHRS $1.03
- ELA $6.04
- Resistance Level
- CHRS $1.23
- ELA $7.05
- Average True Range (ATR)
- CHRS 0.13
- ELA 0.34
- MACD
- CHRS -0.02
- ELA -0.06
- Stochastic Oscillator
- CHRS 38.89
- ELA 48.63
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ELA Envela Corporation
Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.